芦可替尼乳膏快速改善特应性皮炎瘙痒并与生物标志物相关
SCRATCH-AD开放标签研究纳入46例成人特应性皮炎患者,每日两次涂抹1.5%芦可替尼乳膏28天。第2天瘙痒峰值NRS较基线平均下降3.4,第29天下降5.7,皮肤和血清生物标志物下调并与病情改善相关,无严重治疗中出现的不良事件。
要点
- 1.5%芦可替尼乳膏每日两次可快速减轻成人AD瘙痒。
- 瘙痒改善伴随CCL17等AD相关生物标志物下调。
- 研究期间未报告严重治疗中出现的不良事件。
核心结论
- 成人AD患者涂抹1.5%芦可替尼乳膏后瘙痒和临床体征快速持续改善,且与AD生物标志物变化相关。
研究设计与样本
- 开放标签SCRATCH-AD研究(NCT04839380),纳入46例IGA≥2且PP-NRS≥4的成人AD患者,每日两次涂抹1.5%芦可替尼乳膏于所有皮损区域(除外手掌、足底、头皮、生殖器及皱褶,≤20%体表面积)共28天。
主要发现
- 第2天PP-NRS(最严重瘙痒,24小时回忆;主要终点)较基线平均变化为-3.4,第29天为-5.7。
- 改良PP-NRS(当前瘙痒)较基线平均变化在15分钟内达-2.3。
- 皮肤(胶带剥离采样)和血清中CCL17、基质金属蛋白酶12等AD相关生物标志物下调,并与疾病和症状严重度改善相关。
- 未报告严重治疗中出现的不良事件。
临床怎么用
- 对于IGA≥2且PP-NRS≥4的成人AD患者,可考虑使用1.5%芦可替尼乳膏每日两次涂抹于受累区域(除外特定部位,≤20%体表面积)以快速改善瘙痒和体征。
局限性
- 本研究为开放标签设计,样本量46例,缺乏对照组,需谨慎解读因果关联。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
To address the need for rapid reduction of atopic dermatitis (AD) clinical manifestations, this study investigated the time course of the effects of ruxolitinib (selective JAK1/JAK2 inhibitor) cream on itch and associated changes in skin and serum biomarkers in adults with AD. In the open-label SCRATCH-AD study (NCT04839380), patients with AD, an Investigator's Global Assessment score ≥2, and a Peak Pruritus Numerical Rating Scale score ≥4 applied 1.5% ruxolitinib cream to all affected areas (except palms, soles, scalp, genitals, and folds; ≤20% body surface area) twice daily for 28 days. Among 46 patients, the mean change from baseline in Peak Pruritus Numerical Rating Scale was -3.4 on day 2 (worst itch, 24-hour recall; primary endpoint) and -5.7 on day 29. Mean change from baseline in modified Peak Pruritus Numerical Rating Scale (current itch) was -2.3 by 15 minutes. Skin (sampled with tape strips) and serum biomarkers associated with AD, such as CCL17 and matrix metalloproteinase 12, were downregulated with ruxolitinib cream and correlated with improvements in disease and symptom severity. There were no serious treatment-emergent adverse events. In summary, patients with AD who applied 1.5% ruxolitinib cream experienced rapid and sustained improvement in itch and clinical improvements that correlated with changes in AD biomarkers.
引用
- Bissonnette R, Saint-Cyr Proulx E, Correa da Rosa J, et al. Ruxolitinib cream demonstrated rapid reductions in itch and atopic dermatitis signs that correlated with biomarkers. J Invest Dermatol. 2025. PMID: 41265829. doi:10.1016/j.jid.2025.10.613
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。